您的当前位置:首页 > 行业数据 > 表7、全球主要获批、在研中重度AD系统治疗靶向药对比
图片属性
图片格式:PNG 图片大小:227KB 图片尺寸:2376*1182
同报告图片
 / 4
表7、全球主要获批、在研中重度AD系统治疗靶向药对比_第1页
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
表7、全球主要获批、在研中重度AD系统治疗靶向药对比_第2页
表7、全球主要获批、在研中重度AD系统治疗靶向药对比_第3页
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
表7、全球主要获批、在研中重度AD系统治疗靶向药对比_第4页
fCDpnbbngrkgICB8IOiNr+WQjSAgICAgICAgIHwg5YWs5Y+4ICAgfCDlm73lrrboja/nm5HlsYDmibnlh4bpgILlupTnl4fml7bpl7QgfAp8LS0tLS0tLS18LS0tLS0tLS0tLS0tLS18LS0tLS0tLS18LS0tLS0tLS0tLS0tLS0tLS0tLS0tLS0tLS18CnwgSUwgLSAxN0EgfCDlj7jlupPlpYflsKTljZXmipcgfCDor7rljY4gICB8IDIwMjDlubQgICAgICAgICAgICAgICAgICAgfAp8IElMIC0gMTdBIHwg5L6d5aWH54+g5Y2V5oqXICAgfCDnpLzmnaUgICB8IDIwMjLlubQgICAgICAgICAgICAgICAgICAgfAp8IElMIC0gMTdBIHwg5aSr6YKj5aWH54+g5Y2V5oqXIHwg5oGS55Ge5Yy76I2vIHwgMjAyNeW5tDTmnIggICAgICAgICAgICAgICAgIHwKfCBJTCAtIDE3QSB8IOi1m+eri+Wlh+WNleaKlyAgIHwg5pm657+U6YeR5rOwIHwgMjAyNOW5tDjmnIggICAgICAgICAgICAgICAgIHwKCui1hOaWmeadpea6kO+8muWMu+iNr+mtlOaWue+8jOWFtOS4muivgeWIuOe7j+a1juS4jumHkeiejeeglOeptumZouaVtOeQhg==
表7、全球主要获批、在研中重度AD系统治疗靶向药对比_第5页
所属报告: 荃信生物~B(2509.HK)-港股公司研究报告:深耕自免疾病治疗领域携手罗氏将发挥自免双抗平台国际潜力-260101(34页).pdf
打包全文图表

相关数据

客服
商务合作
小程序
服务号
折叠